Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 774

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 774
---
 change to the Series A Preferred stock for the three months ended September 30, 2024, or 2023.

Common stock

During the three months ended September 30,
2024, the Company issued 2 shares of common stock on vesting of restricted stock units during the period. The Company also issued 2 and 7 shares of common stock, representing the Series C Preferred Stock 25% dividend and automatic conversion of
outstanding Series C Preferred Stock, respectively, on the fourth anniversary of issuance.

During the three months ended September 30, 2023, the Company issued 2 shares
of common stock, representing the Series C Preferred Stock 20% dividend the third anniversary of issuance.

2017 Omnibus Incentive Plan

As subsequently approved by the Company’s stockholders at an annual meeting of stockholders, on April 11, 2018, the
Company’s board of directors approved the adoption of the Company’s 2017 Omnibus Equity Incentive Plan (the “2017 Plan”), as amended. The board of directors also approved a form of Performance Stock Unit Award Agreement to be
used in connection with grants of performance stock units (“PSUs”) as well as a Restricted Stock Unit (“RSU”) award under the 2017 Plan. As approved by the Company’s stockholders on June 21, 2022, the number of common
shares available under the 2017 Plan as of September 30, 2024, is 13 shares, less the number of shares of common stock issued under the Del Mar (BC) 2013 Amended and Restated Stock Option Plan (the “Legacy Plan”), or that are subject
to grants of stock options made, or that may be made, under the Legacy Plan, or that have been previously exercised.

F-41

The following table sets forth the aggregate information on all equity compensation plans as of September 30, 2024:

| Plan (in thousands, except per share                                                       
 amounts)                                                                                   |     | Number of shares of          
 common stock to be issued    
 upon exercise of outstanding 
 stock options and            
 rights                       
 (a)                          |   |     | Weighted-average  
 exercise price of 
 stock options and 
 rights            
 $                 |           |     | Number of shares of common stock          
 remaining available for future issuance   
 under equity compensation                 
 plans                                     
 (excluding securities reflected in column 
 (a))(2)                                   |   |
| Equity compensation plans approved by security holders